

**TYPE OF CANCER:** Refractory or metastatic cancer  
**TYPE OF TRIAL:** Phase I  
**TRIAL SPONSOR:** Endocyte

**PRINCIPAL INVESTIGATOR:** Wolfram Samlowski, M.D.  
**CONTACT PERSON:** Sandy Lahr  
(702) 822-5174

### **STUDY SUMMARY**

This study is a multi-center, nonrandomized, open-label, dose-escalating Phase 1 investigation of EC0225 being carried out in patients with refractory or metastatic cancer who have exhausted standard therapeutic options. All patients will undergo a nuclear imaging procedure (Folate Scan) utilizing the investigational agent 99mTc-EC20 during the screening period to assess tumor folate receptor status.

### **TREATMENT OVERVIEW**

The drug is given as a bolus intravenous dose on Day 1, 3, 5, 8, 10 and 12 of a 4-week cycle. Minimum length of patient participation is anticipated to be 12 weeks (two 4-week cycles followed by a 30-day follow-up period).

### **PRETREATMENT ASSESMENT**

- Signed informed consent
- Documentation of concomitant medication
- Physical Examination
- Vital signs: Weight, height, ECOG performance evaluation
- Serum pregnancy test for all women of child bearing age
- Tumor markers if clinically indicated
- Hematology
- Serum chemistry
- Urinalysis
- Retrieval of paraffin-embedded tumor sample for consenting patients
- Folate scan
- Disease Evaluation- FDG – PET/CT, CT scans and Physical Exam
- Beginning with initial dose of 99mTc-EC20, monitor Adverse events and Serious adverse effects (SAEs)

## **ENTRANCE CRITERIA FOR PARTICIPATION IN TRIAL**

### **Inclusion Criteria**

To qualify for enrollment, the following criteria must be met:

- 1) Written informed consent must be obtained from the patient.
- 2) Participants must be  $\geq 18$  years of age.
- 3) Patients must have a histologic or cytologic diagnosis of neoplasm.
- 4) No effective standard therapeutic options.
- 5) Performance status of 0-2 on the Eastern Cooperative Oncology Group (ECOG) scale (Appendix 1).
- 6)  $\geq 4$  weeks (prior to EC0225 Cycle 1 Week 1 Day1) from therapeutic radiation or patients must have recovered (or returned to baseline) from any acute toxicity associated with prior cytotoxic therapy. Patients who have previously received noncytotoxic therapy (e.g. EGFR, VEGF TKIs, etc) and who have recovered from drug associated toxicity (or who have “controlled” toxicity such as VEGF induced hypertension) are allowed to enter the trial after a “drug washout” period consisting of 4 half-lives of the agent.
- 7) Patient compliance and geographic proximity (as determined by the Principal Investigator) that allow adequate follow-up.
- 8) Women of childbearing potential must have a “negative” serum pregnancy test within one week prior to treatment with investigational agents.
- 9) Adequate organ function including:
  - a) Bone Marrow Reserve: Absolute neutrophil count (ANC)  $\geq 1.5 \times 10^9/L$  prior to treatment. Patients on maintenance doses of G-CSF will be eligible for enrollment. Platelets  $\geq 100 \times 10^9/L$  and hemoglobin  $\geq 9$  g/dL (patients may not receive prophylactic transfusion or erythropoiesis stimulators in order to qualify for trial eligibility). Patients on maintenance doses of erythropoiesis stimulators for treatment of chronic secondary anemia at the time of enrollment will be eligible.
  - b) Hepatic: Total Bilirubin  $\leq 1.3 \times$  ULN and serum transaminase levels  $\leq 2.5 \times$  ULN.
  - c) Renal: Serum creatinine  $\leq 1.5 \times$  ULN or creatinine clearance  $\geq 60$  mL/min/1.73m<sup>2</sup> for patients with serum creatinine levels above 1.5 x ULN.
- 10) Willingness to practice contraceptive methods.

Note: The effect of EC0225 upon a developing fetus or nursing infant is unknown; therefore, women with childbearing potential who are sexually active should

- 1) Use an effective birth control method [e.g., oral, transdermal or injectable contraceptives, IUD, double-barrier contraception (such as diaphragm and spermicidal jelly)] or
- 2) Have had a prior history of surgically-induced sterility (i.e., tubal ligation, etc.). In addition, men with childbearing potential who are sexually active should practice an effective method of birth control (e.g., condom and spermicidal jelly). Effective birth control methods should be used throughout study participation and for at least 3 months following the last dose of study drug.

## **Exclusion Criteria**

The presence of any of the following will exclude the patient from the study:

- 1) Concurrent malignancies.
- 2) Concurrent serious (as determined by the Principal Investigator) medical conditions.
- 3) Women who are pregnant or lactating.
- 4) Patients with evidence of symptomatic brain metastases.
- 5) Patients receiving concomitant anticancer therapy (excluding supportive care).  
(Hormonal maintenance therapy is acceptable.)
- 6) Patients requiring palliative radiotherapy at the time of study entry.
- 7) Patients unable to tolerate conditions for radionuclide imaging.
- 8) Patients who have been administered another radiopharmaceutical that would interfere with the assessment of  $^{99m}\text{Tc}$ -EC20.